Clinical Trials Logo

Clinical Trial Summary

Nowadays, frozen-thawed embryo transfers (FET) are expending. This practice avoids risk of ovarian hyperstimulation syndrome (OHSS), as well as allowing better synchronization between endometrium and embryo, which is fundamental for pregnancy. There are several FET protocols, including hormonal replacement therapy cycle (HRT), which enable clinicians to adapt the day of embryo transfer. However, increase in spontaneous miscarriages was observed with this latter protocol compared to fresh embryo transfers and the other endometrial preparations (natural and stimulated), in relation with the lack of physiological corpus luteum. Then, Clinicians interrogate about measuring serum progesterone in order to adjust their treatment and/or transfer date. Various studies have shown thresholds below and/or above which pregnancy or live birth rate were lowered. The main objective is to find a serum progesterone threshold on the day of embryo transfer above which live birth rate is increased. The secondary objectives are to analyze the factors associated with increased serum progesterone on the day of transfer, to analyze the miscarriage rate, and impact of change on luteal phase support on day 12.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Ovarian Hyperstimulation Syndrome

NCT number NCT05588635
Study type Observational
Source Centre Hospitalier Régional Metz-Thionville
Contact
Status Completed
Phase
Start date November 1, 2019
Completion date March 1, 2021

See also
  Status Clinical Trial Phase
Withdrawn NCT00617864 - The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome N/A
Withdrawn NCT01979341 - The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes N/A
Completed NCT01427335 - Calcium for Prevention of Ovarian Hyperstimulation Syndrome Phase 3
Completed NCT01014104 - Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome Phase 1/Phase 2
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Completed NCT06333691 - Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin N/A
Terminated NCT01714648 - Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome? Phase 4
Completed NCT01500863 - Endometrial Receptivity After GnRH Agonist Triggering Phase 4
Recruiting NCT00417144 - Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Phase 4
Completed NCT03876145 - The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome N/A
Not yet recruiting NCT02392520 - Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS) N/A
Completed NCT00835523 - Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist N/A
Completed NCT00665041 - Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome Phase 2
Active, not recruiting NCT05638529 - Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome Phase 4
Not yet recruiting NCT03071172 - Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET Phase 3
Recruiting NCT02084940 - Long Acting GnRH Antagonist in PCOS Women Undergoing IVF N/A
Completed NCT01815138 - Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Phase 4
Completed NCT00867659 - The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors N/A
Completed NCT01569256 - Ovarian Hyperstimulation Syndrome and Cabergoline N/A
Not yet recruiting NCT05198128 - Ovarian Hyperstimulation Syndrome Using Calcium Infusion N/A